La Jolla Pharmaceutical Company – Vasodilatory Shock

Submitted By:
Published Date:
January 25, 2020

Access Program Information

The primary objective of the study is to provide access to LJPC-501 for distributive shock
patients who remain hypotensive despite receiving fluid and vasopressor therapy.

Rare Disease:
Osteochondritis dissecans